Pfizer Inc.PFENYSE
Loading
A large-scale business, with solid profitability, with revenues declining valued in line with the market.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Comprehensive financial statement data for deep analysis
| Metric | Dec 21 | Dec 22 | Dec 23 | Dec 24 | Dec 25 |
|---|---|---|---|---|---|
| Return on Equity | - | - | - | - | - |
| Return on Invested Capital | - | - | - | - | - |
| Gross Margin | 57.7% | 61.9%↑7.3% | 50.9%↓17.7% | 65.8%↑29.1% | 70.3%↑6.9% |
| Operating Margin | 25.6% | 37.4%↑46.3% | 8.9%↓76.3% | 25.9%↑191.5% | 24.7%↓4.8% |
| Net Margin | 27.2% | 31.3%↑14.7% | 3.6%↓88.5% | 12.6%↑251.9% | 12.4%↓1.5% |
| Earnings Yield | - | - | - | - | - |